MAY 24, 2019 02:36 PM PDT

New Therapeutic Target for Depression

WRITTEN BY: Nouran Amin

In a study published in the Journal of Psychopharmacology, a new drug target for the treatment of depression has been identified by researchers at the Department of Human Physiology of the UMA Faculty of Medicine.

The study stemmed from the research group, “Neurochemistry of the Transmission in the Central Nervous System”, co-directed by Professor Zaida Díaz-Cabiale, where they identified ‘GAL (1-15)’--part of the neuropeptide molecule called Galanin.

Galanin is central to the common symptom of depression—anhedonia, the loss of pleasure in daily activities.

“We have verified through different experiments how animals modify their response to high-reinforcement appetitive stimuli, such as saccharine or sexual attraction, after the administration of the Galanin fragment”, explains researcher Carmelo Millón, one of the authors of this study. “The understanding of these mechanisms opens the way for endless therapeutic strategies, hence its importance.”

Researchers from Karolinska Institute in Sweden also collaborated on the study and examined the molecular interactions of brain reinforcement system. They observed that the brains' ability to support positive behavior was inhibited by the Galanin fragment which reaffirmed the initial findings.

Most therapeutics for depression are SSRIs (selective serotonin reuptake inhibitors)—such drugs can take up to two weeks to start showing signs of treatment with a further 30 percent of patients who receive the medication are resistant to the treatment.

Learn more about the future of depression treatments:

Source: Drug Target Review

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 25, 2019
Drug Discovery
AUG 25, 2019
New Viable Drug Target for Prostate Cancer
In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell...
AUG 25, 2019
Drug Discovery
AUG 25, 2019
Potential Drug Target for Stroke Patients
In a study published in Science, a proton-activated chloride channel (PAC) may serve as a drug target to protect against the tissue-damaging effects of str...
AUG 25, 2019
Drug Discovery
AUG 25, 2019
Drug Combination May Combat Deadly Drug-Resistant Fungus
A drug combination of anti-fungal and anti-bacterial medications may be effective against the spread of a highly infectious and deadly fungus--Candida auri...
AUG 25, 2019
Cancer
AUG 25, 2019
Using VR to Design Medicine
Being able to visualize and precisely understand molecular shapes is a key factor in drug design. Over the years, to envision and better understand molecul...
AUG 25, 2019
Drug Discovery
AUG 25, 2019
How Does Ecstasy Cure PTSD?
Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewir...
AUG 25, 2019
Drug Discovery
AUG 25, 2019
What's the Difference Between Therapy and MDMA Therapy?
From a first glance, MDMA-assisted therapy may look very different from mainstream therapies such as Cognitive Behavioral Therapy (CBT); patients lying on...
Loading Comments...